The treatment of COVID-19 with pruamine was breakthrough: significantly reduced hospitalization and sepsis rates

At present, the global new crown pneumonia epidemic (COVID-19) situation is still serious, and the domestic local outbreak is also a return, vaccines and special-effects drugs are the international medical community and the national public is one of the most important concerns.
recently, Pioneer Pharmaceuticals announced the latest breakthrough in clinical trials in Brazil for the treatment of Prudrumide COVID-19.
results showed that psyruamine may significantly reduce the severity of coVID-19 patients from mild to severe disease by reducing TMPRSS2 and ACE-2 expression.
It is understood that psythonamine is a new generation of androgen-borne (AR) antagonists developed by pioneering the pharmaceutical industry, which can be used in the treatment of tumor and non-tumor AR-related diseases, and is currently undergoing Phase I-III clinical trials in China and the United States for the treatment of prostate and breast cancer.
seems to be out of step with COVID-19 plucoline can achieve such outstanding efficacy and good safety in the treatment, is it "uninsponsive willow", or "water into the canal"? Let's turn our time back to the early stages of the neo-crown outbreak, where epidemiological studies have shown that COVID-19 has a higher rate of disease progression and fatality in male patients than in women, which also leads to speculation about whether androgens are associated with neo-coronavirus (SARS-CoV-2) infection.
other years, Pioneer Pharmaceuticals conducted clinical research cooperation with Guo Qiang, Director of the First Hospital affiliated with Suzhou University, and Professor Zhou Weifeng of Suzhou University Medical Department to explore the potential mechanisms leading to COVID-19 gender differences.
study found that AR signals may play a role in disease progression and death in men with COVID-19, and that AR inhibitors that block them are potential new therapies for coVID-19 men, especially in severe patients.
further results show that plucamine, while blocking AR signals, can reduce the expression of ACE-2 and TMPRSS2 proteins, two key proteins that the new coronavirus enters the host cell.
also inhibits the expression of induced nitric oxide enzyme (iNOS) and tumor necrotizing factor-α (TNF alpha) in macrophage-active markers in mice.
these results support the role of AR signaling in disease progression and death in COVID-19 male patients.
note that, as of now, plucoline is the first small molecule drug that regulates the expression of ACE-2 and TMPRSS2 proteins and has the potential for coVID-19 treatment.
In June 2020, Dr. Andy Goren, a professor at Brown University and chief medical officer of Applied Biology, published research findings on the potential association between androgen hair loss and the pathogenesis of COVID-19, providing a scientific basis for androgen-inhibitor antagonists to intervene in COVID-19 as an early drug, and prompting Applied Biology to explore further.
then, based on in vitro research and patient clinical findings, Pioneer Pharmaceuticals and Appleed Biology of the United States reached a clinical trial of Prueline's treatment of COVID-19 male patients on July 13, 2020.
In order to alleviate the global epidemic, it took the pioneering pharmaceutical industry to work with relevant researchers to complete a series of tasks such as the improvement of clinical programmes, the approval of Brazilian drug regulatory departments and hospitals, and drug transportation, and the first subjects in the group on August 20th and all subjects on October 25th.
subsequent clinical trials initially showed positive results.
25 November, the clinical trial expanded to include 168 female subjects, based on positive results demonstrated by psyruamine in the treatment of COVID-19 male subjects.
December 11, Pioneer Pharmaceuticals learned from Dr. Andy Goren, director of the Clinical Research Program, that the preliminary results of the clinical trial of Prueline's treatment of COVID-19 showed outstanding results and good safety.
The preliminary results of the clinical trial included 319 subjects, with the main endpoints being the percentage of subjects hospitalized for COVID-19 within 30 days and the clinical symptom assessment (using a 7-point scale, such as the use of ventilators and the percentage of deaths).
Based on preliminary results analysis of 114 subjects of the psyruamine group and 100 subjects in the placebo control group, the hospitalization rate in the psython group was 0.8 per cent, the percentage of deaths was 0 per cent for the use of ventilators and 0 per cent for the control group, while the hospitalization rate for the control group was 27 per cent, the percentage of use of ventilators was 9.0 per cent and the percentage of deaths was 2 per cent.
we can see the percentage of rtPCR positive tests for this clinical trial from day 0 to day 30 (as of December 8, 2020) from the table below.
from day 7, there was a significant decrease in the control group compared to patients who were positive for pruethylamine, a trend that continued until the 30th day of results.
as an AR antagonist, can be used for short-term medication (1-2 weeks) for the treatment of coviD-19 new crown patients, and the safety is controllable.
that the final clinical study of the clinical trial will be completed in January 2021.
To date, the cumulative number of confirmed cases of neo-crown pneumonia worldwide has reached nearly 70 million, and psylone can significantly reduce the deterioration of COVID-19 patients from minor to severe, thereby significantly reducing hospitalization and ICU use, and promoting a reduction in COVID-19-related mortality.
Currently, Pioneer Pharmaceuticals is actively preparing for Phase III clinical trials in China and the United States, and hopes to obtain emergency authorization for the treatment of COVID-19 with psyruamine, so that more COVID-19 patients can benefit from Pcloone's treatment as soon as possible, thus contributing to the ultimate success in the fight against the epidemic.
Bioaversing Source: Biological Exploration Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mays Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here